Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy

Neurology

Volumn 53, Issue 3, 1999, Pages 580-591

  Greene, Douglas A ^a,d   Arezzo, J C ^c   Brown, M B ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; CI 1014; PLACEBO; SORBITOL; UNCLASSIFIED DRUG; ZENARESTAT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG POTENCY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYELINATED NERVE; NERVE BIOPSY; NERVE CONDUCTION; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURAL NERVE;

EID: 0033546655     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.3.580     Document Type: Article

References (45)

1. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978;1:168-188.
2. Young MJ, Boulton AJM, Macleod AF, Williams DRR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic populations. Diabetologia 1993;36:150-154.
3. Division of Diabetes Translation Center for Disease Control, American Diabetes Association, National Center for Health Statistics, The Bureau of the Census. Diabetes in America. 2nd ed. NIH publication no. 95-1468. Bethesda, MD: National Institutes of Diabetes and Digestive and Kidney Diseases, 1995.
4. Brand PW. The diabetic foot. In: Ellenberg M, Rifkin H, eds. Diabetes mellitus. New York: Medical Examination Publishing, 1982:829-849.
5. Thomas PK, Brown MJ. Diabetic polyneuropathy. In Dyck PJ, Asbury AK, Winegrad AI, Porte D, eds. Diabetic neuropathy. Philadelphia: WB Saunders, 1987:56-65.
6. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
7. The DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995;122:561-568.
8. Jakobsen J, Christiansen JS, Kristoffersen I, et al. Autonomic and somatosensory nerve function after 2 years of continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes 1988;37:452-455.
9. The St. Thomas' Diabetic Study Group. Failure of improved glycaemic control to reverse diabetic autonomic neuropathy. Diabet Med 1986;3:330-334.
10. Navarro X, Kennedy WR, Aeppli D, Sutherland DER. Neuropathy and mortality in diabetes: influence of pancreas transplantation. Muscle Nerve 1996;19:1009-1016.
11. Stevens MJ, Feldman EL, Greene DA. The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Diabet Med 1995;12:566-579.
12. Tomlinson DR, Stevens EJ, Diemel LT. Aldose reductase inhibitors and their potential for the treatment of diabetic complications. Trends Pharmacol Sci 1994;15:293-297.
13. Greene DA, Winegrad AI. In vitro studies of the substrates for energy production and the effects of insulin on glucose utilization in the neural components of peripheral nerve. Diabetes 1979;28:878-887.
14. Cameron NE, Cotter MA, Hohman TC. Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide metabolism in the neurovascular deficit of diabetic rats. Diabetologia 1996;39:172-182.
15. Tomlinson DR, Fernyhough P, Diemel LT, Maeda K. Deficient neurotrophic support in the aetiology of diabetic neuropathy. Diabet Med 1996;13:679-681.
16. Mizisin AP, Calcutt NA, DiStefano PS, Acheson A, Longo FM. Aldose reductase inhibition increases CNTF-like bioactivity and protein in sciatic nerves from galactose-fed and normal rats. Diabetes 1997;46:647-652.
17. Yagihashi S, Kamijo M, Ido Y, Mirrlees DJ. Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy: ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats. Diabetes 1990;39:690-696.
18. Sima AA, Bril V, Nathaniel V, et al. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med 1988;319:548-555.
19. Greene DA, Bril V, Sima AAF. The relevance and efficacy of aldose reductase inhibitors in human diabetic neuropathy. In Ward J, Goto Y, eds. Diabetic neuropathy. Chichester, UK: John Wiley & Sons, 1990:133-142.
20. Frank RN. The aldose reductase controversy. Diabetes 1994; 43:169-172.
21. Florkowski CM, Rowe BR, Nightingale S, Harvey TC, Barnett AH Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy. Diabetes 1991;40:129-133.
22. Ao S, Shingu Y, Kikuchi C, et al. Characterization of a novel aldose reductase inhibitor, FR74366, and its effects on diabetic cataract and neuropathy in the rat. Metabolism 1991;40: 77-87.
23. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Neurology 1992; 42:1823-1839.
24. Williams DA. A test for difference between treatment means when several dose levels are compared with a zero dose control. Biometrics 1971;27:103-117.
25. Williams DA. The comparison of several dose levels with a zero dose response. Biometrics 1972;28:519-531.
26. American Diabetes Association. Report and recommendations of the San Antonio Conference on Diabetic Neuropathy. Diabetes 1988;37:1000-1004.
27. Sima AA, Brown MB, Prashar A, Chakrabarti S, Laudadio C, Greene DA. The reproducibility and sensitivity of sural nerve morphometry in the assessment of diabetic peripheral polyneuropathy. Diabetologia 1992;35:560-569.
28. Judzewitsch RG, Jaspan JB, Polonsky KS, et al. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med 1983;308:119-125.
29. Kimura J. Electrodiagnosis in diseases of nerve and muscle: principles and practice. Philadelphia: FA Davis, 1989.
30. Greene DA, Brown MB. Validation of sural nerve fiber density and percent normal teased fibers as morphological endpoints in clinical trials of diabetic neuropathy. In: Hotta N, Greene DA, Ward JD, Sima AAF, Boulton AJM, eds. Diabetic neuropathy: new concepts and insights. Amsterdam: Exerpta Medica, Elsevier, 1995:379-385.
31. Sima AA, Greene DA, Brown MB, et al. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy: the Tolrestat Study Group. J Diabetes Complications 1993;7:157-169.
32. Green DM, Swets JA. Signal detection theory and psychophysics. New York: John Wiley & Sons, 1966.
33. Dyck PJ, Karnes JL, Daube J, O'Brien P, Service FJ. Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy. Brain 1985;108:861-880.
34. Thomas PK, Berthold CH, Ochoa J. Microscopic anatomy of the peripheral nervous system. In Dyck PJ, Thomas PK, et al, eds. Peripheral neuropathy. 3rd ed. Philadelphia: WB Saunders, 1993:71-72.
35. Britland ST, Young RJ, Sharma AK, Clarke BF. Association of painful and painless diabetic polyneuropathy with different patterns of nerve fiber degeneration and regeneration. Diabetes 1990;39:898-908.
36. Sima AA, Nathaniel V, Bril V, McEwen TA, Greene DA. Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy. J Clin Invest 1988;81:349-364.
37. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:89-94.
38. Russell JW, Karnes JL, Dyck PJ. Sural nerve myelinated fiber density differences associated with meaningful changes in clinical and electrophysiologic measurements. J Neurol Sci 1996;135:114-117.
39. Troni W, Carta Q, Cantello R, Caselle MT, Rainero I. Peripheral nerve function and metabolic control in diabetes mellitus. Ann Neurol 1984;16:178-183.
40. Arezzo JC. The use of electrophysiology for the assessment of diabetic neuropathy. Neuroscience Research Communications 1997;21:13-23.
41. Llewelyn JG, Thomas PK, Gilbey SG, Watkins PJ, Muddle JR. Pattern of myelinated fibre loss in the sural nerve m neuropathy related to type 1 (insulin-dependent) diabetes. Diabetologia 1988;31:162-167.
42. Vogt RC. Robust extraction of axon fibers from large-scale electron micrograph mosaics. In Maragos P, Schafer RW, Butt MA, eds Mathematical morphology and its applications to image and signal processing. Atlanta: Kluwer, 1996:433-441.
43. Boulton AJM, Levins S, Comstock J. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 1990;33:431-437.
44. Sorbinil Retinopathy Trial Research Group. The sorbinil retinopathy trial: neuropathy results. Neurology 1993;43:1141-1149
45. Hohman TC, Bochenek WJ, Meng X, Neefe L, Beg M, The ARI-509 Development Team. Nerve function and biochemistry in diabetic patients treated with ARI-509, a novel aldose reductase inhibitor. Diabetologia 1997;40(suppl 1):A552. Abstract.